The research conducted by the American Medical Association and the Centers for Disease Control and Prevention revealed a substantial increase in spending on glucagon-like peptide-1 receptor agonists from 2018 to 2023, with semaglutide and tirzepatide products contributing significantly to the rise.

By 2023, these products accounted for 70% of all spending on GLP-1 RAs, with a market share shift observed. The study analyzed data capturing 85% of retail and 74% of mail order prescription fills, adjusted for inflation using 2023 dollars. It acknowledged limitations related to the analysis of sales at compounding pharmacies, prescription indications, and adjustments for rebates and discounts. The researchers highlighted the potential impact of expanded indications and coverage determinations on future demand and spending.

Source: JAMA Network Open